ANG Lifesciences India Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025, following Board approval on February 14, 2026. The company reported comprehensive standalone and consolidated results prepared in accordance with SEBI regulations.

Financial Performance Overview

The company's standalone financial results for Q3 FY26 showed mixed performance across key metrics. Revenue from operations and other comprehensive financial data were disclosed as part of the quarterly reporting cycle.

Segment-wise Performance

The consolidated results reflect the company's two primary business segments. The pharmaceuticals segment and printing & packaging segment through subsidiary Mansa Print & Publishers Limited showed varied performance patterns.

Board Meeting and Regulatory Compliance

The Board of Directors convened on Saturday, February 14, 2026, to consider and approve the standalone and consolidated unaudited financial results. The meeting commenced at 05:00 PM and concluded at 07:20 PM. The results were prepared pursuant to Regulation 30 & 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Auditor Review and Business Operations

The company's statutory auditors, M/s Khurana Sharma & Co., Chartered Accountants, issued a limited review report on the unaudited financial results. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410. ANG Lifesciences operates as a pharmaceutical manufacturing company with products including Liquid Injections, Vials, Ampoules, Hard Gelatin capsules, and various therapeutic formulations covering Antibiotics, Antiviral, Antimalarial, and other major categories.

The financial results are available on the company's website at www.anglifesciences.com and on the Bombay Stock Exchange website at www.bseindia.com .

ANG Lifesciences India Limited has announced its board meeting schedule to review quarterly financial performance and conduct other necessary business matters.

Board Meeting Details

The pharmaceutical company has scheduled a board meeting for February 14, 2026, at 05:00 P.M. at its registered office located at Darbara Complex, SCO-113, District Shopping Centre, B Block, Ranjit Avenue, Amritsar-143001. The meeting has been convened in accordance with Regulation 29 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015.

Agenda Items

The board will address several key business matters during the scheduled meeting:

• Consider and approve standalone and consolidated unaudited financial results for the quarter ended December 31, 2025
• Review financial performance for the nine months ended December 31, 2025
• Address any other business matters deemed necessary with the Chairman's permission

Trading Window Restrictions

In compliance with SEBI regulations on insider trading prevention, ANG Lifesciences has implemented specific trading restrictions. The trading window closure began on January 1, 2026, and will remain in effect until 48 hours after the financial results are made public on February 14, 2026. This measure aligns with the company's Code of Conduct for Prevention of Insider Trading and Fair Disclosure of Unpublished Price Sensitive Information.

Company Operations

ANG Lifesciences operates multiple manufacturing facilities across Himachal Pradesh, including units in Baddi and surrounding areas. The company maintains its registered office in Amritsar, Punjab, and conducts pharmaceutical manufacturing operations through its various production units located in Solan district.